Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo

Cancer Science

Volumn 101, Issue 1, 2010, Pages 143-148

  Umezu, Tomokazu ^a   Shibata, Kiyosumi ^a   Shimaoka, Maiko ^a   Kajiyama, Hiroaki ^a   Yamamoto, Eiko ^a   Ino, Kazuhiko ^a   Nawa, Akihiro ^a   Senga, Takeshi ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; PACLITAXEL; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; FEMALE; GENE SILENCING; GLYPICANS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 71849105157     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01382.x     Document Type: Article

References (26)

1. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72:278-87.
2. Markman M, Liu PY, Wilczynski S. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460-5.
3. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
4. Pectasides D, Fountzilas G, Aravantinos G. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006, 102:285-91.
5. Sugiyama T, Kamura T, Kigawa J. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-9.
6. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989, 32:342-9.
7. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
8. Desbordes SC, Sanson B. The glypican Dally-like is required for Hedgehog signalling in the embryonic epidermis of Drosophila. Development 2003, 130:6245-55.
9. Hagihara K, Watanabe K, Chun J, Yamaguchi Y. Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 2000, 219:353-67.
10. Ohkawara B, Yamamoto TS, Tada M, Ueno N. Role of glypican 4 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 2003, 130:2129-38.
11. Song HH, Shi W, Filmus J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997, 272:7574-7.
12. Tsuda M, Kamimura K, Nakato H. The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila. Nature 1999, 400:276-80.
13. Toretsky JA, Zitomersky NL, Eskenazi AE. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001, 23:496-9.
14. Yamauchi N, Watanabe A, Hishinuma M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18:1591-8.
15. Maeda D, Ota S, Takazawa Y. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009, 27:894-904.
16. Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol 2007, 26:341-4.
17. Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008, 130:224-30.
18. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003, 63:2278-83.
19. Kajiyama H, Shibata K, Terauchi M. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res 2005, 11:1798-808.
20. Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 2004, 23:945-55.
21. Chevillard S, Pouillart P, Beldjord C. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996, 77:292-300.
22. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003, 56:45-56.
23. Gonzalez AD, Kaya M, Shi W. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998, 141:1407-14.
24. Komori H, Nakatsura T, Senju S. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12:2689-97.
25. Motomura Y, Senju S, Nakatsura T. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006, 66:2414-22.
26. Nakatsura T, Komori H, Kubo T. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004, 10:8630-40.